One of the first modern pharma factory of yesteryears was commissioned
by Ipca at Mumbai in 1969. The company was originally promoted by a
group of medical professionals and businessmen and was incorporated
as 'The Indian Pharmaceutical Combine Association Limited.' in
October 1949. The present management took over in November 1975 when
the total turnover of the company was just Rs. 0.54 crores.
Currently, this premise where Ipca started its operations, houses the
Registered Office of the company. Key departments like International
Marketing, R&D (Formulations) and Analytical Development Lab are
1949 - Ipca Laboratories Ltd. was incorporated on 19th October, in
Mumbai, under the name `The Indian Pharmaceutical Combine Association
Limited'. The Company manufacture pharmaceutical products such as
tablets, capsules, vials and ampoules. The Company was promoted by a
group of medical professionals viz., Dr. N.K. Chaina, Dr. A.M. Desai,
Dr. N.S. Tibrawala, K.M. Shroff, S.F. Kirawal, U.H. Dalal and K.B.
1964 - The name was subsequently changed to `Ipca Laboratories Ltd.'
on 6th August 1964. The name was further changed to `Ipca
Laboratories Private Limited' on 13th January 1966. The name of the
company was again changed to `Ipca Laboratories Ltd.' on 9th August
1988. The company became a Public Limited Company on 24th March,
1975 - The management of the company was taken over by Amitabh
Bachchan, Ajitabh Bachchan, Jaya Bachchan, M.R. Chandurkar, P.C.
1994 - The Company undertook to set up a modern plant at Athal,
Silvassa, for manufacture of pharmaceutical formulations. Plant and
machinery comprising blenders, auto tablet coaters, fluid bed dryers,
etc., procured indigenously. The Tatlam bulk drug unit capacity was
increased to 500 TPA.
1995 - 9,225,000 No. of equity shares allotted to promoters, friends,
relatives and associates (of these, 225,000 were Rights shares at a
premium of Rs 120 per share). During February, the Company issued
3,275,000 No. of equity shares of Rs 10 each at a premium of Rs 120
per share of which 150,000 shares reserved for allotment on a
preferential basis to employees of the Company (all were taken up).
Balance 3,125,000 shares issued to the public (all were taken up).
2002-R S Hugar, former managing director of Global Trust Bank, has
joined the board of directors of Ipca as non-executive chairman with
effect from June 11, 2002.
-Launched new domestic marketing division, ACTIVA , dedicated to
Rheumatology Care. First Company in India to have such division for
marketing superspeciality molecules.
- Launched new domestic marketing division,Hy Care dedicated to
- Wholly owned subsidiary ‘Ipca Pharmaceuticals Inc.’ incorporated in
United States of America.
-Wholly owned subsidiary ‘Ipca Laboratories (UK) Ltd.’ incorporated
in United Kingdom.
- Forbes, a leading US business magazine, selected among its top 200
successful, rising companies outside USA, with sales under USD 1
-Members of the Company have approved the amalgamation in the nature
of merger of Innotech Pharma Ltd., a 100% subsidiary of the Company,
-Ipca Laboratories Ltd. unveils novel injectable antibiotic
combination of cefotaxime sodium with sulbactam sodium for the first
time in the country under the brand name 'Sultax'
-Received 'Lifetime Achievement Award' for the year2002-03 from from
CHEMEXIL (Basic Chemicals,Pharmaceuticals & Cosmetics Export
Promotion Council)for export promotion over the years.
-Commissioned new formulation plant at Silvassa
-Forbes Asia, a leading US business magazine selected Ipca, for the
second consecutive year as one among the first 200 'Best under a
Billion Company' in Asia
-Ipca Laboratories Ltd has informed that the Company has entered into
a Joint Venture (JV) agreement with Chongqing Holley Holding Company
Ltd of China.
-Merger of Innotech Pharma Limited with Ipca Laboratories Limited in
-Acquires Cardiac brand ISORDIL from Wyeth Limited.
-Forbes Asia, a leading US business magazine selected Ipca, for the
third consecutive year as one among the first 200 'Best under a
Billion Company' in Asia.
- Ipca Laboratories has given the Bonus in the Ratio of 1:1
-Ipca Laboratories Enters into Strategic Alliance with Ranbaxy
Pharmaceuticals Inc., for the US Market
-Ipca Laboratories launches fixed dose ACT combination and stops
manufacturing of single ingredient Oral Artemisinin derivatives.
-Ipca's new plant at Dehradun commenced operation on 5th May, 2006
-Ipca - Ranbaxy Alliance received U.S. FDA marketing approval for
-Ipca Laboratories granted US FDA approval for Hydroxychloroquine
-Ipca Laboratories - Acquisition of 100% shareholding of formulation
dossier registration holding companies in Australia and N
-Ipca launched eighth domestic marketing division, 'Altus' which
caters to intensivists and surgeons.
-Ipca has been awarded by Forbes Inc., as one of the 'Best under a
Billion' Forbes Global's 200 Best Small Companies, 2007. In the past,
company has received same award for three consecutive years' 2003,
2004 and 2005.
-Ipca Laboratories receives US FDA approval for Propranolol
-Tonira Pharma's Nandesari unit (API plant at Baroda) receives US-FDA
-Ipca Laboratories Ltd has re-appointed Mr. Premchand Godha as the
Managing Director of the Company for a further period of 5 years
w.e.f. April 01, 2008.
-Ipca-Piparia, formulation manufacturing unit receives MHRA-UK
approval. This is the 3rd plant after Athal and Kandla receiving this
-WHO prequalify Ipca's dossier of ARTESUNATE + AMODIAQUINE Co Blister
making Ipca the 2nd company in the world and the first Indian company
to receive this prequalification.
-Ipca received Best Patent Award during the year 2007 - 08
- Ipca Laboratories Ltd has informed that the Board of Directors of
the Company at its meeting held on January 21, 2010, inter alia,
appointed Mr. Anand T Kusre as a Director of the Company.
-Company has splits its Face value of Shares from Rs 10 to Rs 2
-Ipca Laboratories has received approval from UK Medicines and
Healthcare Products Regulatory Agency for its fourth manufacturing
unit at a Special Economic Zone in Indore for good manufacturing
practices under the regulator.
-Ipca labs bags nod to amalgamate Tonira Pharma
-Mr. Dev Parkash Yadava has been appointed as an Additional Director
of the Company
-IPCA Laboratories bags USFDA nod Indore formulations manufacturing
-IPCA received Corporate Citizen Award' for best corporate governance
-IPCA Dehradun won the Energy Conservation Award for the 3rd year in
-IPCA featured on the 8th position in the list of 'India's Most
Admired Companies, in a survey carried out by Fortune India, in
collaboration with The Hay Group, for the second time.
-IPCA Laboratories said that SEZ Indore formulations manufacturing
unit has been found acceptable after the inspection of US-FDA.
-IPCA Laboratories Acquisition of High Potency Oral Solid Dosage
formulations manufacturing unit situated at Pithampur near Indore.
-IPCA has entered into an alliance with Oncobiologics, Inc. USA for
the development, manufacture and commercialization of biosimilar
monoclonal antibody products.
-IPCA Sports Club wins the E-Merck Inter-Pharma Cricket Tournament.
-IPCA acquires formulations manufacturing unit located at Tarapur,
Dist. Palghar, Maharashtra.
-IPCA Sports Club wins Dreamz Trophy (T-20 & 40-overs format).
-New product Launch - Pacimol® Active
-Whistle Blower Policy implemented.